National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES.

 

1963. No. 34

_______

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1962.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1962.

Dated this twenty-first

day of

 April, 1963.

  

DE L ‘ISLE

Governor-General.

By His Excellency’s Command,

  

Minister of State for Health.

_________

 

Amendments of the National Health (Pharmaceutical Benefits) Regulations. 

Commencement.

1.  These Regulations shall come into operation on the first day of May, 1963.

First Schedule.

2.  The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after the words—

“ Hexamethonium Tartrate.”

the words—

“ Hexamethonium Tartrate Injection.”;

(b) by omitting the words—

“ Pyrimethamine Tablets.”;

and

(c) by omitting the words—

“ Suxamethonium Chloride Injection.”.

_______________________________________________________________________________________

* Notified in the Commonwealth Gazette on 26th April, 1963.

 

  Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos 59 and 137; and 1962, Nos. 34, 101 and 114.

2813/63.—Price 5d.  10/8.4.1963.

 

2

Second Schedule.

3.  The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by adding at the end of the second column of the item relating to the pharmaceutical benefit “Chloramphenicol B.P.” the words—

“ Chloramphenicol B.P. with Polymyxin B. Sulphate B.P.”;

(b) by inserting after the item relating to the pharmaceutical benefit “ Cortisone Acetate B.P.” the following item:—

“ Cyclizine Hydrochloride................................ Cyclizine Hydrochloride with Caffeine B.P. and Ergotamine Tartrate B.P.”;

 

(c) by adding at the end of the second column of the item relating to the pharmaceutical benefit “ Ergotamine Tartrate B.P.” the words—

“ Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride ”;

 and

(d) by adding at the end of the item relating to the pharmaceutical benefit “ Polymyxin B. Sulphate B.P.” the words—

“ Polymyxin B. Sulphate B.P. with Chloramphenicol B.P.”.

Third Schedule.

4.  The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after the words—

“ Acetazolamide Sodium.”

the word—

“ Acetohexamide.”;

(b) by inserting after the word and letter—

“ Amphotericin B.”

the word—

“ Ampicillin.”;

(c) by inserting before the word—

“ Cyclopenthiazide.”

the words—

“ Cyclizine Hydrochloride.”;

(d) by omitting the words and letter—

“ Desacetyl Lanatoside, C.”

and inserting in their stead the word—

“ Deslanoside.”;

(e) by inserting after the words—

“ Diphtheria Toxoid Purified.”

the word—

“ Dipyridamole.”;

(f) by inserting after the word—

“ Hydroflumethiazide.”

the word—

“ Hydroxocobalamin.”;

 

(g) by inserting after the words and letters—

3

“ Levorphanol Tartrate, B.P.C.”

the word—

“ Liothyronine.”;

(h) by inserting after the words—

“ Mecholyl Chloride.”

the words—

“ Medroxyprogesterone Acetate.”;

(i) by inserting before the word—

“ Methazolamide.”

the words—

“ Metaraminol.

Metformin.”;

(j) by inserting after the word—

“ Methotrexate.”

the words and letters—

“ Methoxamine Hydrochloride, B.P.C.”;

(k) by inserting after the words and letters—

“ Methylcellulose Mucilage, A.P.F.”

the word—

“ Methyldopa.”;

(l) by inserting after the word—

“ Nandrolone.”

the word—

“ Niclosamide.”;

(m) by inserting after the word—

“ Polydimethylsiloxanes.”

the word—

“ Polythiazide.”;

(n) by omitting the word—

“ Pyrimido-Prymidine.”;

(o) by inserting after the words—

“ Tripolidine Hydrochloride.”

the word—

“ Vadrine”;

and

(p) by inserting before the word—

“ Veriloid.”

the word—

“ Velactin.”.

Fifth Schedule.

5.  The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by inserting after the item relating to the pharmaceutical benefit “ Amphotericin B.” the following item:—

“ Ampicillin..................................................... Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

  

4

(b) by omitting the item relating to the pharmaceutical benefit “ Calciferol Tablets B.P.” and inserting in its stead the following item:—

“ Calciferol Tablets B.P.................................... With the written authority of the Director-General— Idiopathic hypoparathyroidism Chronic hypoparathyroid tetany ”;

 

(c) by inserting after the item relating to the pharmaceutical benefit “ Diiodohydroxyquinoline B.P., Vaginal Tablet ” the following item:—

“ Diiodohydroxyquinoline B.P. Compound Effervescent Gynaecological Pessary................................. Trichomonal and monilial vaginitis ”;

 

(d) by inserting after the item relating to the pharmaceutical benefit “ Diphenhydramine Hydrochloride B.P., Elixir ” the following item:—

“ Dipyridamole Tablets.................................. Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

 

(e) by inserting after the item relating to the pharmaceutical benefit “ Hydrocortisone Sodium Succinate Injection B.P.” the following items:—

“ Hydroxocobalamin Injection, 100 microgramme strength..........................	Established megalocytic anaemia
Hydroxocobalamin Injection,  1,000 microgramme strength...........................	Sub-acute combined degeneration of the cord Neuroblastoma ”

(f) by inserting after the item relating to the pharmaceutical benefit “ Levorphanol Tartrate B.P.C.” the following item:—

“ Liothyronine ............................................   Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

(g) by inserting before the item relating to the pharmaceutical benefit “ Mepyramine Maleate Elixir ” the following items: —

“ Mebhydrolin Suspension ..................................................................	Any disease or condition in a child under the age of twelve years
Medroxyprogesterone Acetate ..................................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

(h) by omitting the item relating to the pharmaceutical benefit “ Methyl Prednisolone Acetate ” and inserting in its stead the following item:—

“ Methyldopa .................................................................   Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

 

5

(i) by omitting the item relating to the pharmaceutical benefit “ Polydimethylsiloxanes ” and inserting in its stead the following items:—

“ Pituitary Posterior Lobe B.P.C., Insufflation	Diabetes insipidus
Polydimethylsiloxanes .....................................	Ileostomy or colostomy conditions
Polythiazide ..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital ”;

 

(j) By inserting after the item relating to the pharmaceutical benefit “ Pyridine Aldoxime Methiodide ” the following item:—

“ Pyridoxine Hydrochloride, Oral Tablet, B.P.C. Peripheral neuritis due to isoniazid therapy ”;

and

(k) by omitting the item relating to the pharmaceutical benefit “ Vancomycin Hydrochloride ” and inserting in its stead the following items:—

“ Vadrine............................................................... Vancomycin Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
Velactin .......................................................		With the written authority of the the Director-General, galactosaemia ”.

 

_____________________

By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra.